Does Selective β1 Blockade with Landiolol Improve Mortality After Coronary Artery Bypass Graft Surgery?

Anesth Analg. 2024 Apr 1;138(4):e17-e18. doi: 10.1213/ANE.0000000000006913. Epub 2024 Mar 15.

Authors

Miyu Kinoshita¹, Amir L Butt², Hiroyuki Kinoshita³, Kenichi A Tanaka⁴

Affiliations

¹ Department of Anesthesiology, Reading Hospital - Tower Health, West Reading, Pennsylvania.
² Department of Anesthesiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, Amir-Butt@ouhsc.edu.
³ Department of Dental Anesthesiology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
⁴ Department of Anesthesiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.

PMID: 38489802
DOI: 10.1213/ANE.0000000000006913

No abstract available

MeSH terms

Adrenergic beta-Antagonists* / therapeutic use
Coronary Artery Bypass* / adverse effects
Morpholines
Treatment Outcome
Urea / analogs & derivatives*
Urea / therapeutic use

Substances

landiolol
Adrenergic beta-Antagonists
Morpholines
Urea